![](https://investorshub.advfn.com/uicon/461558.png?cb=1569947577)
Wednesday, June 19, 2024 7:39:47 PM
All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106
Outpatient administration was allowed and found to be feasible
Currently no FDA-approved CAR-T treatments for WM
Data presented at the European Hematology Association 2024 Hybrid Congress
WORCESTER, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T-cell therapy, show a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer. MB-106 is being developed in a collaboration between Mustang and Fred Hutch Cancer Center (“Fred Hutch”) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).
Recent MBIO News
- Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/21/2024 08:01:58 PM
- Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/20/2024 12:00:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/20/2024 12:00:26 PM
- Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy • GlobeNewswire Inc. • 06/17/2024 12:30:30 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/13/2024 04:15:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:00:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 12:35:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 12:33:33 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/31/2024 09:09:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:15:26 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/13/2024 10:01:30 AM
- Mustang Bio Announces Closing of $4 Million Public Offering • GlobeNewswire Inc. • 05/02/2024 08:01:07 PM
- Mustang Bio Announces Pricing of $4 Million Public Offering • GlobeNewswire Inc. • 04/30/2024 12:00:07 AM
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases • GlobeNewswire Inc. • 03/28/2024 01:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:30:31 PM
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/11/2024 08:05:12 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 08:02:09 PM
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma • GlobeNewswire Inc. • 03/07/2024 12:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:07:36 PM
- Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/11/2024 01:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:05:12 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:06:38 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/12/2023 02:52:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:37:55 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM